Ultragenyx: Outstanding Q4 2018 Results [Seeking Alpha]
Ultragenyx Pharmaceutical Inc. (RARE)
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ultragenyx.com/investor-relations
Company Research
Source: Seeking Alpha
Ultragenyx: Outstanding Q4 2018 Results Summary Ultragenyx released strong Q4 '18 results with a successful commercial launch of Crysvita and Mepsevii. Upcoming DTX 301/401 phase 1/2 cohort 2/3 data in H2 2019 are major near-term catalysts. The stock is trading at a premium EV/REV multiple compared to the larger biotech peers. Ultragenyx Pharmaceutical ( RARE President and CEO of Ultragenyx Emil D. Kakkis, M.D., Ph.D., stated: This last year was important for Ultragenyx as we successfully launched two therapies internationally and validated clinical data from our gene therapy platform. In 2019 we look forward to expanding the global commercial reach of our approved therapies, submitting a New Drug Application for a third, and advancing our gene therapy platform toward pivotal studies." Source: Press Release 10-K Filing The company reported total GAAP revenues of $16.2 million in Q4 '18 or up 573% Y/Y, beating the analysts' estimates of $13.6 million. Crysvita net product sales were $1
Show less
Read more
Impact Snapshot
Event Time:
RARE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RARE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RARE alerts
High impacting Ultragenyx Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
RARE
News
- Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study [Yahoo! Finance]Yahoo! Finance
- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $48.00 price target on the stock.MarketBeat
- Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102 [Yahoo! Finance]Yahoo! Finance
- Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102GlobeNewswire
- Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome [Yahoo! Finance]Yahoo! Finance
RARE
Earnings
- 2/15/24 - Beat
RARE
Sec Filings
- 4/18/24 - Form 4
- 4/15/24 - Form 8-K
- 3/12/24 - Form 4
- RARE's page on the SEC website